(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

NCT03837821 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Abemaciclib

Sponsor

Weill Medical College of Cornell University

Collaborators

Eli Lilly and Company